Outcomes in cystic fibrosis lung transplant recipients infected with organisms labeled as pan-resistant: An ISHLT Registry‒based analysis
Section snippets
Registry
We conducted a retrospective cohort analysis utilizing the ISHLT Thoracic Transplant Registry, an international longitudinal database collecting data from the pre- and post-transplant periods. Data are collected from 345 international institutions; the ISHLT has data-sharing agreements with 10 data collectives that provide registry data for the majority of the participating institutions, although some institutions individually contribute data as well. A list of institutions can be found in the
Results
The final study population consisted of 3,256 patients with CF. There were 607 patients in the group labeled as having pan-resistant infection, and there were 2,649 control subjects.
Discussion
The prevailing organ scarcity in LT has made it necessary to carefully select patients with ideally a high likelihood of successful outcome.11 Pre-transplant chronic infection or infection with MDR/pan-resistant bacteria has historically been regarded a contraindication for LT at many centers, in some cases even an absolute contraindication.11 However, several small, single-center studies have shown that survival is not generally impaired in those carrying MDR bacteria.14, 15, 19
Through
Disclosure statement
The authors have no conflicts of interest to disclose.
References (26)
- et al.
The Registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart‒lung transplantation report—2017; Focus theme: Allograft ischemic time
J Heart Lung Transplant
(2017) - et al.
Association of lung perfusion disparity and mortality in patients with cystic fibrosis awaiting lung transplantation
J Heart Lung Transplant
(2002) - et al.
Analysis of cystic fibrosis referrals for lung transplantation
Chest
(1995) - et al.
A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation
J Heart Lung Transplant
(2015) - et al.
Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis
Chest
(2016) - et al.
The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre
J Hosp Infect
(2004) - et al.
Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria
J Heart Lung Transplant
(2007) - et al.
Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation
J Heart Lung Transplant
(2007) - et al.
Changing demographics and outcomes of lung transplantation recipients with cystic fibrosis
J Heart Lung Transplant
(2016) - et al.
Survival benefit of induction immunosuppression in cystic fibrosis lung transplant recipients
J Cyst Fibros
(2015)
Clinical and demographic factors associated with post‒lung transplantation survival in individuals with cystic fibrosis
J Heart Lung Transplant
Lung transplantation for cystic fibrosis: results, indications, complications, and controversies
Semin Respir Crit Care Med
Cystic fibrosis mortality and survival in the UK: 1947-2003
Eur Respir J
Cited by (14)
Lung transplantation for cystic fibrosis and bronchiectasis
2023, Revue des Maladies RespiratoiresUpdate on Lung Transplantation for Cystic Fibrosis
2022, Clinics in Chest MedicineCitation Excerpt :Both groups had very good outcomes, leading to the conclusion that patients with more resistant Pseudomonas species should not be excluded from consideration for transplantation.33 A more recent registry analysis confirmed this conclusion.34 There remains considerable debate regarding whether patients infected with Burkholderia species are appropriate candidates for lung transplantation.
Cystic fibrosis
2021, The LancetCitation Excerpt :Some consider chronic infections with pathogens (eg, Burkholderia cenocepacia or M abscessus) absolute contraindications. However, an analysis of more than 3000 lung transplant recipients with such pathogens showed no significant association with a 90-day or 1-year mortality.114 Cystic fibrosis-related comorbidities (ie, gastro-oesophageal reflux disease, cystic fibrosis-related diabetes, bone disease [particularly with systemic glucocorticoid treatment], and kidney disease) affect outcomes and require optimisation.
Phage Therapy in Lung Transplantation: Current Status and Future Possibilities
2023, Clinical Infectious Diseases